Relapse rate of HR patients with or without TP53/KRAS variants
| . | Relapse . | No relapse . | Total . |
|---|---|---|---|
| TP53/KRAS positive | 8 (89%) | 1 | 9 |
| TP53/KRAS negative | 61 (34%) | 118 | 179 |
| Total | 69 (37%) | 119 | 188 |
| . | Relapse . | No relapse . | Total . |
|---|---|---|---|
| TP53/KRAS positive | 8 (89%) | 1 | 9 |
| TP53/KRAS negative | 61 (34%) | 118 | 179 |
| Total | 69 (37%) | 119 | 188 |
In the group of patients with HR treatment response, 89% of patients with TP53 and/or KRAS variants experienced a relapse. In contrast, only 34% of the remaining 179 patients without such variants relapsed later on.